TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$37.34
0.53 (1.44%)
▲
5d:
+1.55%
30d:
+19.76%
90d:
+9.31%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TEVA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TEVA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.68
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$40.16
7.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $37.34, which is considered extended relative to its 30-day fair value range of $31.75 to $36.47. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.0) compared to its historical average (10.8). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $37.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TEVA scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.40 (+12.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $37.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TEVA scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.40 (+12.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$31.75 -
$36.47
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
27.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($41.40)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$31.75 -
$36.47
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$35.00
Resistance Level
$37.83
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.97
Wall Street Target
$41.40
(+12.5%)
Revenue Growth (YoY)
-0.8%
Earnings Growth (YoY)
72.2%
Profit Margin
4.1%
Valuation Premium vs History
+3.6% premium
PE vs Historical
12.0 vs 10.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$38.14
(+4%)
2-Year Target
$39.51
(+7%)
3-Year Target
$40.93
(+11%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$36.93
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 43.5%)
$182.50
(+396%)
Base:
(SPY PE: 12.0, Growth: 43.5%)
$108.83
(+196%)
Bear:
(PE: 10.2, Growth: 43.5%)
$92.51
(+151%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Forward PE: 17.64 | Forward EPS (Implied): $2.12
Bull Case
$45.09
(+21%)
Analyst growth 15.0%, PE expands to 18.5
Base Case
$37.34
(0%)
Market implied 0.0%, PE stable at 17.6
Bear Case
$28.57
(-24%)
Severe decline -15.0%, PE contracts to 15.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 8:40 AM ET
Data refreshes hourly during market hours. Next update: 9:40 AM
Data refreshes hourly during market hours. Next update: 9:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Sabag
SELL
62102 shares
2026-03-17
Brian Savage
SELL
1127 shares
2026-03-05
Christine Fox
SELL
7924 shares
2026-03-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
